GlassScriptPhysician profile
Fang Zhou
NPI 1356513394
$10,619.80
in general payments reported to CMS, 2019-2025
42 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $898 · 2021: $1,978 · 2022: $1,670 · 2023: $1,576 · 2024: $1,529 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,527 · Education: $20.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.14 |
| Education | $20.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,867.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,800.58 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,509.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $582.40 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $550.62 | 2019-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $533.15 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Abbvie INC. | $470.63 | 2020-2025 | Ubrelvy |
| Pfizer INC. | $341.62 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $280.49 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.02 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $204.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $152.07 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $141.39 | 2020-2023 | Linzess |
| Abbott Laboratories | $105.74 | 2024-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $96.41 | 2019 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $74.93 | 2022 | |
| Xeris Pharmaceuticals, INC. | $74.77 | 2022-2025 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $65.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.75 | 2021-2023 | Trintellix |
| Eisai INC. | $48.78 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $39.12 | 2022-2024 | Quviviq |
| Amgen INC. | $34.96 | 2024-2025 | Repatha, Otezla, Repatha |
| Arbor Pharmaceuticals, INC. | $30.92 | 2020-2021 | |
| Ardelyx, INC. | $29.08 | 2024 | Ibsrela |
| Exact Sciences Corporation | $27.31 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $24.29 | 2019-2021 | |
| Abiomed | $23.57 | 2024 | Impella |
| Genentech USA, INC. | $23.21 | 2019-2021 | |
| Vivus LLC | $21.20 | 2019 | |
| Edwards Lifesciences Corporation | $20.66 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cepheid | $20.51 | 2025 | Genexpert |
| Shire North American Group INC | $19.42 | 2019 | |
| Gilead Sciences, INC. | $16.91 | 2025 | |
| Optos, INC. | $15.95 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.64 | 2019 | |
| Recor Medical INC | $15.45 | 2025 | Paradise Ultrasound Renal Denervation System |
| Shield Therapeutics INC | $15.23 | 2024 | |
| Horizon Therapeutics Plc | $12.87 | 2022 | |
| Melinta Therapeutics, LLC | $12.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.83 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.62 | 2020 | |
| Allergan, INC. | $7.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fang Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.